Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1207)
•••
Post by Duster340on Jul 15, 2022 1:43pm
130 Views
Post# 34827492

davgro/czechcashing You are wright

davgro/czechcashing You are wrightit makes no sense. why would i bash my own stock NDVA i still own and underwater on.
below is my post on theTGIF board kind of funny the stock was trading at 2 cents haha

June 21, 2022 - 10:23 AM
123 Reads
Post# 34771031

Looks Like TGIF

is heading towards 2 cents, and then ( o )( o )'s up . just my 2 cents worth lol

( my post @ june 21st 10:23 am and then czechcashing hijacks it and posts on the ndva board @ june 21st 10:51 am  because he knows i own shares there)  below is that post

June 21, 2022 - 10:51 AM
109 Reads
Post# 34771137

Looks Like NDVA

is heading towards 10 cents, and then ( o )( o )'s up . just my 2 cents worth lol

duster writes: you have to ask your self why would i bash my own shares when i own the stock and underwater.  this proves it davgro is busted he is one sick piece of sh*t . some of you guys are blind and seem to ignore the facts. you kind of remind me of republicans. mic drop i just left the building  lol

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities